Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy

BACKGROUND: The therapeutic application of T cells endowing with chimeric antigen receptors (CARs) is faced with “on-target, off-tumor” toxicity against solid tumors, particularly in the treatment of the pancreatic cancer. To our best knowledge, the pancreatic cancer cell line AsPC-1 often highly ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Erhao, Yang, Peiwei, Gu, Jieyi, Wu, Heming, Chi, Xiaowei, Liu, Chen, Wang, Ying, Xue, Jianpeng, Qi, Weiyan, Sun, Qingbo, Zhang, Shengnan, Hu, Jialiang, Xu, Hanmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090669/
https://www.ncbi.nlm.nih.gov/pubmed/30103775
http://dx.doi.org/10.1186/s13045-018-0646-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090669/
https://www.ncbi.nlm.nih.gov/pubmed/30103775
http://dx.doi.org/10.1186/s13045-018-0646-9

Ejemplares similares